A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma is a type of blood cancer affecting plasma cells, which are a type of white blood cell. This study tests a combination of two drugs, talquetamab and teclistamab, to see if they work together to fight this cancer. The study will last around 5 years and has three parts: finding the right dose, checking safety, and seeing if the drugs help patients who have relapsed (cancer returned) or have Refractory Multiple Myeloma (cancer not responding to treatment). Participants must have tried other treatments that didn't work before joining. They will be monitored closely, with visits and follow-ups for up to 2 years after starting the new treatment.

• Study duration is approximately 5 years with regular visits and check-ups.
• This study is only for patients whose previous treatments have failed.
• Participants will be monitored for safety and effectiveness throughout the study.

Participants should have a good health status, not currently involved in other treatments, and no serious health issues like nervous system involvement or certain other blood disorders.